Key Takeaway: Molecular Partners has reported its H1 2026 financial results, highlighting the progress of DLL3-targeting Radio-DARPin MP0712, which is now recruiting at dose level 2 in its Phase 1/2a trial. Initial data is anticipated in 2026, with efficacy results expected in 2027. Additionally, CD70 has been selected as a new radio target for kidney cancer treatment.
Market Sentiment Analysis
POSITIVE FACTORS
MP0712 is advancing to a higher dose level in the trial.
Initial data from the trial is expected in 2026.
The selection of CD70 as a new target indicates innovation.
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+104%
120-day peak, hindsight
Typical move
8.3%
average across 2 past catalysts
Lead asset
ensovibep
Phase 2 · Covid19
Full Press Release Details
DLL3-targeting Radio-DARPin MP0712 progressing in Phase 1/2a trial, now recruiting at dose level 2; initial data expected in 2026, efficacy data expected in 2027 CD70 selected as new radio target for the treatment of kidney cancer and other indications, with clinical program start anticipated in
Frequently Asked Questions
What is MP0712?
MP0712 is a DLL3-targeting Radio-DARPin currently in a Phase 1/2a trial.
What are the key updates from the H1 2026 report?
The report highlights MP0712's advancement to dose level 2 and new target CD70.
When is initial data expected for MP0712?
Initial data from the MP0712 trial is expected in 2026.
What is the new target selected for kidney cancer?
CD70 has been selected as a new radio target for kidney cancer treatment.